Baird lowered the firm’s price target on iRhythm (IRTC) to $79 from $100 and keeps an Outperform rating on the shares. The firm said its tough to again stick their neck out for a name that has had several product timeline delays and they are cautiously optimistic that the voluntary-delay now accounts for prior “unknowns” associated with the ongoing Warning Letter/483-observation remediation process.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Faces Potential Stockholder Dilution and Market Pressure from 2029 Notes Conversion
- iRhythm price target lowered to $125 from $137 at Canaccord
- iRhythm Technologies Reports Strong Revenue Growth in Q3 2024
- iRhythm gets FDA 510(k) clearance for design modifications to Zio AT device
- iRhythm reports Q3 EPS($1.26) , consensus (57c)